Fantastic News! Allist Pharmaceuticals Welcome Prestigious Scientists to Join Science Advisory Broad (SAB)

March 2nd, 2023, Allist Pharmaceuticals (“Allist”) officially established the Science Advisory Broad (SAB) to advance the company’s innovations and business strategies. The broad is comprised of knowledgeable and well-known scientists who have successful experience and capabilities in various medical and scientific areas. The broad will assist Allist’s leadership including analysis in market and the trend of scientific development, review of any project pitching, oversight of project developments, participation of due diligence in asset license-in and collaborations, guidance of key clinical developments, and the establishment of a skillful team.


Mr. Jinhao Du, chairman in Allist Pharmaceuticals, believed that, “based on the concept of innovatively developing for the care of lives, Allist has always insisted on self-developing and providing the innovative drugs for the massive. This is one of our great advantages and is also the key to achieve the long-term success. The join of two scientists in our Science Advisory Broad will provide closed guidance to our internal team for a further development in science and will ensure our development strategy can always meet the changes to our people and the market.”


Mr. Jie Hu, vice chairman in Allist Pharmaceuticals, stated that “it was such a great pleasure that Dr. Bing Yao and Dr. Yong Ben decided to join Allist’s Science Advisory Broad. They are extraordinary scientists and entrepreneurs who have tremendous experience in the industry, successful achievements in their own career paths, and the visions in both China and global-wise. Their join will be an extra assistance in Allist’s development in scientific strategies, pipeline designs, clinical development improvements to enhance the capability of Allist’s research and development.”


Allist’s Science Advisory Broad Members (followed by surname) including:


Bing Yao

Dr. Bing Yao is the Chief Executive Officer and Chairman of ArriVent Biopharma. Dr. Yao is an accomplished executive and scientist with more than 28 years of experience in the biotechnology and pharmaceutical industry. Most recently, he served as Chairman and CEO of Viela Bio, which he co-founded in 2018. In 2021, Viela Bio was acquired by Horizon Therapeutics for $3 billion. Prior to his role at Viela, he served as Senior Vice President of R&D and Head of Respiratory, Inflammation & Autoimmunity at MedImmune and as Senior Vice President, Head of Immuno-Oncology Franchise at AstraZeneca. During his tenure at MedImmune and AstraZeneca, he played key leadership roles in the development and approval of multiple novel biologics for autoimmune, respiratory, and immune-oncology indications, respectively. Prior to joining MedImmune, Dr. Yao led the project team leaders group for immunology, neurosciences, virology, and metabolism for Genentech, and prior to that, served as Vice President of Research and Corporate Officer for Tanox before it was acquired by Genentech. Earlier in his career, Dr. Yao held key roles at Aventis and Amgen. Dr. Yao has authored more than 50 peer-reviewed publications and holds over 20 patents and patent applications.

Yong Ben

Yong (Ben) Ben, M.D., MBA, has over 20 years of medical experience in academia and pharmaceutical & biotech companies, including clinical practice, drug discovery and development in oncology. Until recently, Dr. Ben served as CMO, Solid Tumors, for BeiGene, a global biotechnology company where under his leadership, multiple molecules were approved by health authorities in over ten indications. Ppreviously, Dr. Ben was the CMO at BioAtla, a San Diego based biotechnology company. Prior to that, he was global clinical leader of immuno-oncology clinical development at AstraZeneca, leading the approval of durvalumab in urothelial cancer. Dr. Ben’s career highlights also include his work on the approval of ixazomib in multiple myeloma at Millennium Pharmaceuticals and the approval of axitinib in renal cancer at Pfizer.

Throughout his career, Dr. Ben has led wide-spectrum clinical development efforts from Phase I to Phase 3 trials from strategy planning, and study execution, to BLA/NDA submissions. He started his career as a surgical oncologist at Peking Union Medical College Hospital and completed a postdoctoral fellowship at California Pacific Medical Center. Dr. Ben received his medical degree from Norman Bethune College of Medicine and his MBA from the University of California, San Diego.